Celldex’s CSU drug could challenge a Novartis candidate after PhII

Celldex Therapeutics’ anti-KIT antibody hit the primary endpoint in a mid-stage test in chronic spontaneous urticaria, with some analysts describing the data as better than a Novartis therapy that’s further ahead in development.

Celldex’s Phase II trial set three doses of barzolvolimab against placebo in 208…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks